Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
731.77
-12.67 (-1.70%)
At close: Apr 28, 2026, 4:00 PM EDT
733.22
+1.45 (0.20%)
After-hours: Apr 28, 2026, 7:57 PM EDT
Regeneron Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 4,505 | 4,413 | 3,954 | 4,338 | 8,075 | Upgrade
|
| Depreciation & Amortization | 543.7 | 482.9 | 421 | 341.4 | 286.2 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | 195 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -946.1 | -118.3 | 266.4 | 36.8 | -387 | Upgrade
|
| Stock-Based Compensation | 993.7 | 982.8 | 885 | 725 | 601.7 | Upgrade
|
| Other Operating Activities | -649.9 | -721.2 | -837.9 | -378.4 | 421.6 | Upgrade
|
| Change in Accounts Receivable | 498.1 | -554 | -338.8 | 707.8 | -1,927 | Upgrade
|
| Change in Inventory | -275.3 | -619.7 | -271.7 | -696.5 | -494.3 | Upgrade
|
| Change in Accounts Payable | 736.8 | 735.1 | 598.6 | -138.4 | 866.1 | Upgrade
|
| Change in Unearned Revenue | -51.7 | 227.8 | 37.9 | 32.4 | -120.2 | Upgrade
|
| Change in Other Net Operating Assets | -375.3 | -407.5 | -120.1 | -148.6 | -240.7 | Upgrade
|
| Operating Cash Flow | 4,979 | 4,421 | 4,594 | 5,015 | 7,081 | Upgrade
|
| Operating Cash Flow Growth | 12.63% | -3.78% | -8.39% | -29.18% | 170.47% | Upgrade
|
| Capital Expenditures | -898.4 | -755.9 | -718.6 | -590.1 | -551.9 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 20.1 | - | - | - | Upgrade
|
| Cash Acquisitions | -3.3 | -16.5 | -54.9 | -230.3 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -315.3 | -125.7 | -207.8 | -1,027 | - | Upgrade
|
| Investment in Securities | 587.9 | -1,590 | -2,204 | -1,937 | -4,833 | Upgrade
|
| Investing Cash Flow | -629.1 | -2,468 | -3,185 | -3,785 | -5,385 | Upgrade
|
| Issuance of Common Stock | 635.9 | 1,465 | 1,146 | 1,520 | 1,672 | Upgrade
|
| Repurchase of Common Stock | -3,971 | -3,632 | -2,936 | -2,529 | -2,678 | Upgrade
|
| Common Dividends Paid | -370.3 | - | - | - | - | Upgrade
|
| Other Financing Activities | -10.3 | -33.4 | - | - | - | Upgrade
|
| Financing Cash Flow | -3,715 | -2,201 | -1,790 | -1,009 | -1,006 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.3 | -0.7 | -0.4 | - | - | Upgrade
|
| Net Cash Flow | 634.7 | -248.8 | -381.6 | 221.3 | 690.8 | Upgrade
|
| Free Cash Flow | 4,081 | 3,665 | 3,875 | 4,425 | 6,529 | Upgrade
|
| Free Cash Flow Growth | 11.35% | -5.44% | -12.42% | -32.23% | 225.90% | Upgrade
|
| Free Cash Flow Margin | 28.45% | 25.80% | 29.54% | 36.35% | 40.63% | Upgrade
|
| Free Cash Flow Per Share | 37.57 | 31.84 | 34.08 | 38.98 | 58.19 | Upgrade
|
| Cash Interest Paid | 41.6 | 52.6 | 73.1 | 53.7 | 55.8 | Upgrade
|
| Cash Income Tax Paid | 1,253 | 743 | 870.3 | 1,502 | 1,218 | Upgrade
|
| Levered Free Cash Flow | 3,258 | 2,636 | 2,763 | 2,628 | 4,309 | Upgrade
|
| Unlevered Free Cash Flow | 3,286 | 2,670 | 2,808 | 2,665 | 4,345 | Upgrade
|
| Change in Working Capital | 532.6 | -618.3 | -94.1 | -243.3 | -1,917 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.